ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0564

Associations of Sinusitis, Pharyngitis, and Respiratory Tract Disease Burden with Incident Rheumatoid Arthritis

Vanessa Kronzer1, Weixing Huang2, Alessandra Zaccardelli2, Cynthia Crowson3, John Davis1, Robert Vassallo1, Tracy Doyle4, Elena Losina2 and Jeffrey Sparks2, 1Mayo Clinic, Rochester, MN, 2Brigham and Women's Hospital, Boston, MA, 3Mayo Clinic, Eyota, MN, 4Brigham and Women's Hospital, West Roxbury, MA

Meeting: ACR Convergence 2021

Keywords: Anti-CCP, Epidemiology, Respiratory, rheumatoid arthritis, Smoking

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Title: Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Increasing evidence implicates respiratory mucosa in the pathogenesis of rheumatoid arthritis (RA). However, individual respiratory tract diseases, especially of the upper airways, sinuses, and pharynx, have remained relatively understudied for RA risk. We aimed to determine whether specific respiratory tract diseases are associated with rheumatoid arthritis RA development.

Methods: This case-control study was performed within a large, single center biobank. We matched newly diagnosed RA cases to three controls on age, sex, and electronic health record (EHR) history. We identified RA using a validated algorithm incorporating diagnosis codes, medications, and natural language processing, and then confirmed cases by medical record review. We confirmed date of RA diagnosis by medical record review and obtained RA serostatus from clinical laboratory results. “Seropositive” RA included positivity for rheumatoid factor and/or anti-citrullinated protein antibodies. Respiratory tract disease exposure required one inpatient or two outpatient codes two years before index date of RA or matched date (mean positive predictive value 86%). We obtained covariates including smoking status and pack-years from the biobank survey, supplemented by electronic health record data. Conditional logistic regression models calculated odds ratios (OR) for RA with 95% confidence intervals (CI), adjusting for potential confounders including age, sex, length of EHR history, biobank enrollment year, race/ethnicity, education, body mass index, smoking status, and smoking pack-years. We then stratified by serostatus and smoking.

Results: We identified 741 newly diagnosed RA cases and 2,223 controls (both median age 55, 76% female). In the pre-index exposure period, any respiratory tract disease was present in 47% of cases and 42% of controls. Acute sinusitis (OR 1.61, 95% CI:1.05,2.45), chronic sinusitis (OR 2.16, 95% CI:1.39,3.35), and asthma (OR 1.39, 95% CI:1.03,1.87) were associated with increased risk of RA diagnosis (Table 1). Acute respiratory tract disease burden during the pre-index exposure period was also associated with increased RA risk (OR 1.30 per 10 diagnosis codes, 95% CI:1.08,1.55). Acute pharyngitis was associated with seronegative RA (OR 1.68, 95% CI:1.02,2.74) but not seropositive RA; chronic rhinitis/pharyngitis was associated with seropositive RA (OR 2.46, 95% CI:1.01,5.99) but not seronegative RA. Respiratory tract diseases tended towards higher associations with RA in smokers, especially >10 pack-years (OR 1.52, 95% CI:1.02,2.27; p 0.10 for interaction; Table 2).

Conclusion: We identified novel associations of acute/chronic sinusitis, pharyngitis, and acute respiratory tract disease burden with RA risk. These results suggest that the mucosal paradigm of RA pathogenesis may not only involve the lower respiratory tract, but also the upper respiratory tract.


Disclosures: V. Kronzer, None; W. Huang, None; A. Zaccardelli, None; C. Crowson, None; J. Davis, Pfizer, 5; R. Vassallo, Pfizer, 5, Bristol Myers Sqibb, 5, Sun Pharma, 5, Genentech, 5; T. Doyle, Bristol Myers Sqibb, 5, Boehringer Ingelheim, 2, Genentech, 5; E. Losina, None; J. Sparks, Bristol-Myers Squibb, 2, 5, Amgen, 5, Gilead, 2, Inova, 2, Janssen, 2, Optum, 2, Pfizer, 2.

To cite this abstract in AMA style:

Kronzer V, Huang W, Zaccardelli A, Crowson C, Davis J, Vassallo R, Doyle T, Losina E, Sparks J. Associations of Sinusitis, Pharyngitis, and Respiratory Tract Disease Burden with Incident Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/associations-of-sinusitis-pharyngitis-and-respiratory-tract-disease-burden-with-incident-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-of-sinusitis-pharyngitis-and-respiratory-tract-disease-burden-with-incident-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology